BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia

BioNexus Gene Lab Corp

BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.
VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.
Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.
Conditions include IP license agreement; other definitive agreements not yet executed.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.